UC scientists to study generic vs. brand name drugs for transplants L.A. Biz (blog) The funding from the U.S. Food and Drug Administration will support a clinical trial examining the immunosuppressant tacrolimus (Prograf) against two other generic manufacturers in liver and kidney transplant patients. Tacrolimus is a “critical dose ... |
